FDA approves Vosevi for Hepatitis C
The U.S. Food and Drug Administration has approved Vosevi to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis. Vosevi is a fixed-dose, combination tablet containing two previously approved drugs - sofosbuvir and velpatasvir - and a new drug, voxilaprevir.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Cirrhosis | Food and Drug Administration (FDA) | Hepatitis | Hepatitis C | Liver | Liver Disease | Pharmaceuticals | Urology & Nephrology